Primary advanced malignant melanoma of the uterine cervix treated with a combination of nivolumab and concurrent radiotherapy: A case report
•Cervical malignant melanoma is very rare and has no standard treatment.•Nivolumab plus radiotherapy was used as the initial treatment in this case.•Tumor shrinkage and symptom control were achieved with combination therapy.•The patient developed lymph node metastasis and died 16 months after treatm...
Uloženo v:
| Vydáno v: | Current problems in cancer. Case reports Ročník 20; s. 100396 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Elsevier Inc
01.12.2025
|
| Témata: | |
| ISSN: | 2666-6219, 2666-6219 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | •Cervical malignant melanoma is very rare and has no standard treatment.•Nivolumab plus radiotherapy was used as the initial treatment in this case.•Tumor shrinkage and symptom control were achieved with combination therapy.•The patient developed lymph node metastasis and died 16 months after treatment.•This is the first report on use of nivolumab and radiotherapy for cervical melanoma.
Malignant melanoma accounts for 1–4 % of all gynecological malignancies, with most cases originating in the vulva and/or vagina. Primary malignant uterine melanomas are rare. Although there are reports of initial treatment with nivolumab and combination therapy with nivolumab and radiotherapy for recurrent lesions, no standardized treatment protocol has been established. This case report describes a 74-year-old woman diagnosed with International Federation of Gynecology and Obstetrics stage IV primary malignant melanoma of the cervix. Nivolumab and radiotherapy were concurrently administered to the primary lesion, resulting in tumor mass reduction. However, new pelvic lymph node metastases were observed at 6 months. The same combination therapy was administered but proved ineffective, leading to disease progression and death. To our best knowledge, this is the first report on the combined use of immune checkpoint inhibitors and radiotherapy as the initial treatment for primary malignant melanoma of the cervix. In advanced cases, initial treatment may result in primary lesion reduction and symptom control. |
|---|---|
| AbstractList | •Cervical malignant melanoma is very rare and has no standard treatment.•Nivolumab plus radiotherapy was used as the initial treatment in this case.•Tumor shrinkage and symptom control were achieved with combination therapy.•The patient developed lymph node metastasis and died 16 months after treatment.•This is the first report on use of nivolumab and radiotherapy for cervical melanoma.
Malignant melanoma accounts for 1–4 % of all gynecological malignancies, with most cases originating in the vulva and/or vagina. Primary malignant uterine melanomas are rare. Although there are reports of initial treatment with nivolumab and combination therapy with nivolumab and radiotherapy for recurrent lesions, no standardized treatment protocol has been established. This case report describes a 74-year-old woman diagnosed with International Federation of Gynecology and Obstetrics stage IV primary malignant melanoma of the cervix. Nivolumab and radiotherapy were concurrently administered to the primary lesion, resulting in tumor mass reduction. However, new pelvic lymph node metastases were observed at 6 months. The same combination therapy was administered but proved ineffective, leading to disease progression and death. To our best knowledge, this is the first report on the combined use of immune checkpoint inhibitors and radiotherapy as the initial treatment for primary malignant melanoma of the cervix. In advanced cases, initial treatment may result in primary lesion reduction and symptom control. •Cervical malignant melanoma is very rare and has no standard treatment•Nivolumab plus radiotherapy was used as the initial treatment in this case•Tumor shrinkage and symptom control were achieved with combination therapy•The patient developed lymph node metastasis and died 16 months after treatment•This is the first report on use of nivolumab and radiotherapy for cervical melanoma Malignant melanoma accounts for 1–4% of all gynecological malignancies, with most cases originating in the vulva and/or vagina. Primary malignant uterine melanomas are rare. Although there are reports of initial treatment with nivolumab and combination therapy with nivolumab and radiotherapy for recurrent lesions, no standardized treatment protocol has been established. This case report describes a 74-year-old woman diagnosed with International Federation of Gynecology and Obstetrics stage IV primary malignant melanoma of the cervix. Nivolumab and radiotherapy were concurrently administered to the primary lesion, resulting in tumor mass reduction. However, new pelvic lymph node metastases were observed at 6 months. The same combination therapy was administered but proved ineffective, leading to disease progression and death. To our best knowledge, this is the first report on the combined use of immune checkpoint inhibitors and radiotherapy as the initial treatment for primary malignant melanoma of the cervix. In advanced cases, initial treatment may result in primary lesion reduction and symptom control. Highlights•Cervical malignant melanoma is very rare and has no standard treatment •Nivolumab plus radiotherapy was used as the initial treatment in this case •Tumor shrinkage and symptom control were achieved with combination therapy •The patient developed lymph node metastasis and died 16 months after treatment •This is the first report on use of nivolumab and radiotherapy for cervical melanoma |
| ArticleNumber | 100396 |
| Author | Furukawa, Shigenori Miura, Hideki Sato, Tetsu Okabe, Chikako Soeda, Shu Fujimori, Keiya Kato, Asami Kamo, Norihito |
| Author_xml | – sequence: 1 givenname: Norihito surname: Kamo fullname: Kamo, Norihito email: k0810@fmu.ac.jp organization: Department of Obstetrics and Gynecology, Shirakawa Kosei General Hospital, 2-1 Toyochi Kamiyajiro, Shirakawa City, Fukushima 961-0005, Japan – sequence: 2 givenname: Shigenori surname: Furukawa fullname: Furukawa, Shigenori email: s-furu@fmu.ac.jp organization: Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan – sequence: 3 givenname: Asami surname: Kato fullname: Kato, Asami email: askatou@fmu.ac.jp organization: Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan – sequence: 4 givenname: Chikako surname: Okabe fullname: Okabe, Chikako email: chika729@fmu.ac.jp organization: Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan – sequence: 5 givenname: Hideki surname: Miura fullname: Miura, Hideki email: m-hideki@fmu.ac.jp organization: Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan – sequence: 6 givenname: Tetsu surname: Sato fullname: Sato, Tetsu email: tetsus@fmu.ac.jp organization: Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan – sequence: 7 givenname: Shu surname: Soeda fullname: Soeda, Shu email: s-soeda@fmu.ac.jp organization: Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan – sequence: 8 givenname: Keiya surname: Fujimori fullname: Fujimori, Keiya email: fujimori@fmu.ac.jp organization: Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan |
| BookMark | eNqFkdFqFDEUhkOp0Lr2CbzJC-yaZHYyE0WhlGoLhQrqdTiTOWOzziTLSXbrvkMf2ozrhQjSq4STfH9yvvOSnYYYkLHXUqykkPrNZuW2ztFKCVWXiqiMPmHnSmu91Eqa07_2Z-wipY0Q5aaUplmfs6fP5CegA4d-D8FhzycY_fcAIfMJRwhxAh4Hnh-Q7zKSD8gd0t7_5JkQcgEefX7gwF2cOh8g-xhmIPh9HHcTdBxCXw6D2xFhSSXofSxxBNvDW37JHSTkhNtI-RV7McCY8OLPumDfPl5_vbpZ3t1_ur26vFs6VQu9RAnGSIGNNr0wsmtUr7sWtaobM4i6W-NQmfXQtmIudqYxtemU7lvdukrWdbVg1THXUUyJcLDbowUrhZ2d2o397dTOTu3RaaHeHyksX9t7JJucx9mZJ3TZ9tE_w3_4h3ejD97B-AMPmDZxR6F0baVNygr7ZZ7aPLTSsxDrVpaAd_8PePb5X85drNA |
| Cites_doi | 10.1097/PGP.0000000000000480 10.1093/ajcp/46.4.420 10.1001/jamaoncol.2019.1478 10.1186/s12935-021-02407-8 10.3390/diagnostics14050547 10.1016/S0140-6736(24)00317-9 10.3390/cancers14194575 10.1016/j.critrevonc.2011.03.008 10.3389/fonc.2019.00835 10.5402/2011/683020 10.1056/NEJMoa1200690 10.1007/s00795-023-00377-6 |
| ContentType | Journal Article |
| Copyright | 2025 |
| Copyright_xml | – notice: 2025 |
| DBID | 6I. AAFTH AAYXX CITATION |
| DOI | 10.1016/j.cpccr.2025.100396 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-6219 |
| EndPage | 100396 |
| ExternalDocumentID | 10_1016_j_cpccr_2025_100396 S2666621925000481 1_s2_0_S2666621925000481 |
| GroupedDBID | .1- .FO 0R~ 1P~ AAEDW AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL Z5R 6I. AAFTH AAYXX CITATION |
| ID | FETCH-LOGICAL-c2506-e1a9910e769d091b72d6b8e62579f05b4ef394f8808e62b97959b26d868c31553 |
| ISSN | 2666-6219 |
| IngestDate | Thu Nov 27 00:52:33 EST 2025 Sat Nov 29 17:03:59 EST 2025 Sat Nov 29 12:10:57 EST 2025 Sat Nov 29 06:56:12 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Primary malignant melanoma Immune checkpoint inhibitor Cervix Radiotherapy Nivolumab radiotherapy cervix immune checkpoint inhibitor nivolumab primary malignant melanoma |
| Language | English |
| License | This is an open access article under the CC BY license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c2506-e1a9910e769d091b72d6b8e62579f05b4ef394f8808e62b97959b26d868c31553 |
| OpenAccessLink | http://dx.doi.org/10.1016/j.cpccr.2025.100396 |
| PageCount | 1 |
| ParticipantIDs | crossref_primary_10_1016_j_cpccr_2025_100396 elsevier_sciencedirect_doi_10_1016_j_cpccr_2025_100396 elsevier_clinicalkeyesjournals_1_s2_0_S2666621925000481 elsevier_clinicalkey_doi_10_1016_j_cpccr_2025_100396 |
| PublicationCentury | 2000 |
| PublicationDate | December 2025 |
| PublicationDateYYYYMMDD | 2025-12-01 |
| PublicationDate_xml | – month: 12 year: 2025 text: December 2025 |
| PublicationDecade | 2020 |
| PublicationTitle | Current problems in cancer. Case reports |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Mesko, Konecny, Tumeh, Kamrava (bib0012) 2017; 3 Anghel, Georgescu, Serboiu, Marinescu, Aliuș, Georgescu, Mocanu, Sucuri, Stanescu (bib0001) 2024; 14 Pusceddu, Bajetta, Carcangiu, Formisano, Ducceschi, Buzzoni (bib0015) 2012; 81 Topalian, Hodi, Brahmer, Gettinger, Smith, McDermott, Powderly, Carvajal, Sosman, Atkins, Leming, Spigel, Antonia, Horn, Drake, Pardoll, Chen, Sharfman, Anders, Taube, McMiller, Xu, Korman, Jure-Kunkel, Agrawal, McDonald, Kollia, Gupta, Wigginton, Sznol (bib0019) 2012; 366 Norris, Taylor (bib0014) 1966; 46 Lorusso, Xiang, Hasegawa, Scambia, Leiva, Ramos-Elias, Acevedo, Sukhin, Cloven, Pereira de Santana Gomes, Contreras Mejía, Reiss, Ayhan, Lee, Saevets, Zagouri, Gilbert, Sehouli, Tharavichitkul, Lindemann, Lazzari, Chang, Lampé, Zhu, Oaknin, Christiaens, Polterauer, Usami, Li, Yamada, Toker, Keefe, Pignata, Duska (bib0011) 2024; 403 Jiang, Wang, Deng, Xie, Wang (bib0007) 2025; 16 Du, Bai, Si (bib25) 2023; 9 Yu, Wang, He, Shao, Liu, Xiang, Yang, Zeng, He, Ma, Wang, Liu (bib0022) 2022; 12 Theelen, Peulen, Lalezari, van der Noort, de Vries, Aerts, Dumoulin, Bahce, Niemeijer, de Langen, Monkhorst, Baas (bib0018) 2019; 5 Calderón-Salazar, Cantú de Leon, Perez Montiel, Almogabar-Villagrán, Villavicencio, Cetina (bib0003) 2011; 2011 National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in oncology: melanoma: cutaneous, Version 1.2025, Plymouth Meeting, PA, 2025. Capaccione, Doubrovin, Braumuller, Leibowitz, Bhatt, Momen-Heravi, Molotkov, Kissner, Goldner, Soffing, Ali, Mintz (bib0004) 2022; 14 Schonewolf, Jaworski, Allen, McLean, Lao, Schuchter, Tanyi, Taunk (bib0017) 2022; 7 Li, Wang, Shi, Yu (bib0010) 2023; 13 Zhang, Liu, Zhang, Qiao, Zhang, Zhang (bib23) 2022; 7 Vafaei, Zekiy, Khanamir, Zaman, Ghayourvahdat, Azimizonuzi, Zamani (bib0020) 2022; 22 Wolchok, Chiarion-Sileni, Rutkowski, Cowey, Schadendorf, Wagstaff (bib24) 2024 Kim, Chang, Roh, Oh, Chung, Shin, Koom (bib0008) 2019; 9 Konishi, Okamoto, Tokumitsu, Yano, Nasu, Kobayashi (bib0009) 2024; 57 Yin, Yang, Zhang, Tao, Zou, Ren, Liang, Jiang, Zhao, Zhang, Li, Jia (bib0021) 2019; 38 Diakosavvas, Fasoulakis, Kouroupi, Theodora, Inagamova, Tsatsaris, Nikolaou, Frangia-Tsivou, Giatromanolaki, Kontomanolis (bib0005) 2020; 2020 Huang, Zhou, Gong, Li, Huang (bib0018) 2025 Li, Wang, Shi, Yu (bib0020) 2023; 13 Norris, Taylor (bib0007) 1966; 46 Mesko, Konecny, Tumeh, Kamrava (bib0022) 2017; 3 Topalian, Hodi, Brahmer, Gettinger, Smith, McDermott, Powderly, Carvajal, Sosman, Atkins, Leming, Spigel, Antonia, Horn, Drake, Pardoll, Chen, Sharfman, Anders, Taube, McMiller, Xu, Korman, Jure-Kunkel, Agrawal, McDonald, Kollia, Gupta, Wigginton, Sznol (bib0010) 2012; 366 Capaccione, Doubrovin, Braumuller, Leibowitz, Bhatt, Momen-Heravi, Molotkov, Kissner, Goldner, Soffing, Ali, Mintz (bib0003) 2022; 14 Yu, Wang, He, Shao, Liu, Xiang, Yang, Zeng, He, Ma, Wang, Liu (bib0004) 2022; 12 Vafaei, Zekiy, Khanamir, Zaman, Ghayourvahdat, Azimizonuzi, Zamani (bib0002) 2022; 22 Pusceddu, Bajetta, Carcangiu, Formisano, Ducceschi, Buzzoni (bib0006) 2012; 81 Kim, Chang, Roh, Oh, Chung, Shin, Koom (bib0014) 2019; 9 National Comprehensive Cancer Network (NCCN), NCCN clinical practice guidelines in oncology: melanoma: cutaneous, Version 1.2025, Plymouth Meeting, PA, 2025. Konishi, Okamoto, Tokumitsu, Yano, Nasu, Kobayashi (bib0012) 2024; 57 Theelen, Peulen, Lalezari, van der Noort, de Vries, Aerts, Dumoulin, Bahce, Niemeijer, de Langen, Monkhorst, Baas (bib0015) 2019; 5 Jiang, Wang, Deng, Xie, Wang (bib0016) 2025; 16 Calderón-Salazar, Cantú de Leon, Perez Montiel, Almogabar-Villagrán, Villavicencio, Cetina (bib0001) 2011; 2011 Yin, Yang, Zhang, Tao, Zou, Ren, Liang, Jiang, Zhao, Zhang, Li, Jia (bib0008) 2019; 38 Lorusso, Xiang, Hasegawa, Scambia, Leiva, Ramos-Elias, Acevedo, Sukhin, Cloven, Pereira de Santana Gomes, Contreras Mejía, Reiss, Ayhan, Lee, Saevets, Zagouri, Gilbert, Sehouli, Tharavichitkul, Lindemann, Lazzari, Chang, Lampé, Zhu, Oaknin, Christiaens, Polterauer, Usami, Li, Yamada, Toker, Keefe, Pignata, Duska (bib0013) 2024; 403 Rafiq, Lin, Zhang, Chen, Xu (bib0017) 2025; 7 Boseley (bib0019) 2024 Anghel, Georgescu, Serboiu, Marinescu, Aliuș, Georgescu, Mocanu, Sucuri, Stanescu (bib0021) 2024; 14 Schonewolf, Jaworski, Allen, McLean, Lao, Schuchter, Tanyi, Taunk (bib0011) 2022; 7 Rafiq (10.1016/j.cpccr.2025.100396_bib0017) 2025; 7 Theelen (10.1016/j.cpccr.2025.100396_bib0015) 2019; 5 Lorusso (10.1016/j.cpccr.2025.100396_bib0013) 2024; 403 Li (10.1016/j.cpccr.2025.100396_bib0020) 2023; 13 Diakosavvas (10.1016/j.cpccr.2025.100396_bib0005) 2020; 2020 Pusceddu (10.1016/j.cpccr.2025.100396_bib0006) 2012; 81 Topalian (10.1016/j.cpccr.2025.100396_bib0010) 2012; 366 Calderón-Salazar (10.1016/j.cpccr.2025.100396_bib0001) 2011; 2011 Mesko (10.1016/j.cpccr.2025.100396_bib0022) 2017; 3 Yu (10.1016/j.cpccr.2025.100396_bib0004) 2022; 12 Norris (10.1016/j.cpccr.2025.100396_bib0007) 1966; 46 Schonewolf (10.1016/j.cpccr.2025.100396_bib0011) 2022; 7 10.1016/j.cpccr.2025.100396_bib0009 Capaccione (10.1016/j.cpccr.2025.100396_bib0003) 2022; 14 Vafaei (10.1016/j.cpccr.2025.100396_bib0002) 2022; 22 Yin (10.1016/j.cpccr.2025.100396_bib0008) 2019; 38 Boseley (10.1016/j.cpccr.2025.100396_bib0019) 2024 Anghel (10.1016/j.cpccr.2025.100396_bib0021) 2024; 14 Kim (10.1016/j.cpccr.2025.100396_bib0014) 2019; 9 Jiang (10.1016/j.cpccr.2025.100396_bib0016) 2025; 16 Huang (10.1016/j.cpccr.2025.100396_bib0018) 2025 Konishi (10.1016/j.cpccr.2025.100396_bib0012) 2024; 57 |
| References_xml | – volume: 5 start-page: 1276 year: 2019 end-page: 1282 ident: bib0018 article-title: Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial publication-title: JAMA Oncol. – volume: 22 start-page: 2 year: 2022 ident: bib0020 article-title: Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier publication-title: Cancer Cell Int. – volume: 14 start-page: 4575 year: 2022 ident: bib0004 article-title: Evaluating the combined anticancer response of checkpoint inhibitor immunotherapy and FAP-targeted molecular radiotherapy in murine models of melanoma and lung cancer publication-title: Cancers – volume: 13 year: 2023 ident: bib0010 article-title: Immunotherapy for mucosal melanoma: a literature review publication-title: Front. Oncol. – year: 2024 ident: bib24 article-title: Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma publication-title: N. Engl. J. Med. – volume: 81 start-page: 185 year: 2012 end-page: 195 ident: bib0015 article-title: A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer publication-title: Crit. Rev. Oncol. Hematol. – volume: 14 start-page: 547 year: 2024 ident: bib0001 article-title: Optimizing palliative pelvic radiotherapy in gynecological cancers: a systematic review and analysis publication-title: Diagnostics – volume: 2011 year: 2011 ident: bib0003 article-title: Primary malignant melanoma of the uterine cervix treated with ultraradical surgery: a case report publication-title: ISRN Obstet. Gynecol. – volume: 9 start-page: 835 year: 2019 ident: bib0008 article-title: Effect of radiotherapy combined with pembrolizumab on local tumor control in mucosal melanoma patients publication-title: Front. Oncol. – volume: 12 year: 2022 ident: bib0022 article-title: Effective combinations of immunotherapy and radiotherapy for cancer treatment publication-title: Front. Oncol. – volume: 38 start-page: 196 year: 2019 end-page: 203 ident: bib0021 article-title: Primary cervical malignant melanoma: 2 cases and a literature review publication-title: Int. J. Gynecol. Pathol. – volume: 3 year: 2017 ident: bib0012 article-title: Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review publication-title: BJR Case Rep – volume: 16 year: 2025 ident: bib0007 article-title: Immunomodulatory effects of radiotherapy in the tumor microenvironment: current evidence and clinical applications publication-title: Front. Immunol. – volume: 2020 year: 2020 ident: bib0005 article-title: Primary malignant melanoma of the cervix: a case report and a review of the literature publication-title: Case Rep. Oncol. Med. – volume: 46 start-page: 420 year: 1966 end-page: 426 ident: bib0014 article-title: Melanomas of the vagina publication-title: Am. J. Clin. Pathol. – volume: 7 start-page: 289 year: 2022 ident: bib23 article-title: Radiotherapy combined with immunotherapy: the dawn of a new era publication-title: Signal Transduct. Target. Ther. – volume: 57 start-page: 83 year: 2024 end-page: 90 ident: bib0009 article-title: Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series publication-title: Med. Mol. Morphol. – reference: National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in oncology: melanoma: cutaneous, Version 1.2025, Plymouth Meeting, PA, 2025. – volume: 7 year: 2022 ident: bib0017 article-title: Complete response after stereotactic body radiation therapy with concurrent immunotherapy for vaginal melanoma publication-title: Adv. Radiat. Oncol. – volume: 403 start-page: 1341 year: 2024 end-page: 1350 ident: bib0011 article-title: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial publication-title: Lancet – volume: 9 start-page: 00004 year: 2023 ident: bib25 article-title: Immunotherapy for mucosal melanoma publication-title: Oncol. Transl. Med. – volume: 366 start-page: 2443 year: 2012 end-page: 2454 ident: bib0019 article-title: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer publication-title: N. Engl. J. Med. – volume: 9 start-page: 835 year: 2019 ident: bib0014 article-title: Effect of radiotherapy combined with pembrolizumab on local tumor control in mucosal melanoma patients publication-title: Front. Oncol. – volume: 7 year: 2022 ident: bib0011 article-title: Complete response after stereotactic body radiation therapy with concurrent immunotherapy for vaginal melanoma publication-title: Adv. Radiat. Oncol. – volume: 14 start-page: 4575 year: 2022 ident: bib0003 article-title: Evaluating the combined anticancer response of checkpoint inhibitor immunotherapy and FAP-targeted molecular radiotherapy in murine models of melanoma and lung cancer publication-title: Cancers (Basel) – volume: 81 start-page: 185 year: 2012 end-page: 195 ident: bib0006 article-title: A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer publication-title: Crit. Rev. Oncol. Hematol. – reference: National Comprehensive Cancer Network (NCCN), NCCN clinical practice guidelines in oncology: melanoma: cutaneous, Version 1.2025, Plymouth Meeting, PA, 2025. – volume: 12 year: 2022 ident: bib0004 article-title: Effective combinations of immunotherapy and radiotherapy for cancer treatment publication-title: Front. Oncol. – volume: 57 start-page: 83 year: 2024 end-page: 90 ident: bib0012 article-title: Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series publication-title: Med. Mol. Morphol. – volume: 5 start-page: 1276 year: 2019 end-page: 1282 ident: bib0015 article-title: Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial publication-title: JAMA Oncol – volume: 2011 year: 2011 ident: bib0001 article-title: Primary malignant melanoma of the uterine cervix treated with ultraradical surgery: a case report publication-title: ISRN Obstet. Gynecol. – volume: 38 start-page: 196 year: 2019 end-page: 203 ident: bib0008 article-title: Primary cervical malignant melanoma: 2 cases and a literature review publication-title: Int. J. Gynecol. Pathol. – volume: 7 year: 2025 ident: bib0017 article-title: Low-dose radiation therapy reprograms the tumor immune microenvironment to potentiate immune checkpoint blockade publication-title: J. Transl. Oncol. Cancer Res. Rev. – volume: 22 start-page: 2 year: 2022 ident: bib0002 article-title: Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier publication-title: Cancer Cell Int – volume: 13 year: 2023 ident: bib0020 article-title: Immunotherapy for mucosal melanoma: a literature review publication-title: Front. Oncol. – volume: 3 year: 2017 ident: bib0022 article-title: Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review publication-title: BJR Case Rep – volume: 366 start-page: 2443 year: 2012 end-page: 2454 ident: bib0010 article-title: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer publication-title: N. Engl. J. Med. – year: 2024 ident: bib0019 article-title: Double drug treatment raises survival rate for half of advanced melanoma patients to 10 years publication-title: The Guardian – year: 2025 ident: bib0018 article-title: Stereotactic radiation induces systemic T cell clonal expansion and abscopal responses in pembrolizumab-treated patients: multiomic evidence from a phase II study publication-title: Nat. Cancer. – volume: 16 year: 2025 ident: bib0016 article-title: Immunomodulatory effects of radiotherapy in the tumor microenvironment: current evidence and clinical applications publication-title: Front. Immunol. – volume: 14 start-page: 547 year: 2024 ident: bib0021 article-title: Optimizing palliative pelvic radiotherapy in gynecological cancers: a systematic review and analysis publication-title: Diagnostics – volume: 46 start-page: 420 year: 1966 end-page: 426 ident: bib0007 article-title: Melanomas of the vagina publication-title: Am. J. Clin. Pathol. – volume: 403 start-page: 1341 year: 2024 end-page: 1350 ident: bib0013 article-title: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial publication-title: Lancet – volume: 3 year: 2017 ident: 10.1016/j.cpccr.2025.100396_bib0022 article-title: Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review publication-title: BJR Case Rep – volume: 38 start-page: 196 year: 2019 ident: 10.1016/j.cpccr.2025.100396_bib0008 article-title: Primary cervical malignant melanoma: 2 cases and a literature review publication-title: Int. J. Gynecol. Pathol. doi: 10.1097/PGP.0000000000000480 – volume: 46 start-page: 420 year: 1966 ident: 10.1016/j.cpccr.2025.100396_bib0007 article-title: Melanomas of the vagina publication-title: Am. J. Clin. Pathol. doi: 10.1093/ajcp/46.4.420 – volume: 5 start-page: 1276 year: 2019 ident: 10.1016/j.cpccr.2025.100396_bib0015 article-title: Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.1478 – year: 2024 ident: 10.1016/j.cpccr.2025.100396_bib0019 article-title: Double drug treatment raises survival rate for half of advanced melanoma patients to 10 years publication-title: The Guardian – volume: 2020 year: 2020 ident: 10.1016/j.cpccr.2025.100396_bib0005 article-title: Primary malignant melanoma of the cervix: a case report and a review of the literature publication-title: Case Rep. Oncol. Med. – volume: 22 start-page: 2 year: 2022 ident: 10.1016/j.cpccr.2025.100396_bib0002 article-title: Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier publication-title: Cancer Cell Int doi: 10.1186/s12935-021-02407-8 – volume: 7 year: 2022 ident: 10.1016/j.cpccr.2025.100396_bib0011 article-title: Complete response after stereotactic body radiation therapy with concurrent immunotherapy for vaginal melanoma publication-title: Adv. Radiat. Oncol. – year: 2025 ident: 10.1016/j.cpccr.2025.100396_bib0018 article-title: Stereotactic radiation induces systemic T cell clonal expansion and abscopal responses in pembrolizumab-treated patients: multiomic evidence from a phase II study publication-title: Nat. Cancer. – volume: 14 start-page: 547 year: 2024 ident: 10.1016/j.cpccr.2025.100396_bib0021 article-title: Optimizing palliative pelvic radiotherapy in gynecological cancers: a systematic review and analysis publication-title: Diagnostics doi: 10.3390/diagnostics14050547 – volume: 403 start-page: 1341 year: 2024 ident: 10.1016/j.cpccr.2025.100396_bib0013 article-title: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial publication-title: Lancet doi: 10.1016/S0140-6736(24)00317-9 – volume: 7 year: 2025 ident: 10.1016/j.cpccr.2025.100396_bib0017 article-title: Low-dose radiation therapy reprograms the tumor immune microenvironment to potentiate immune checkpoint blockade publication-title: J. Transl. Oncol. Cancer Res. Rev. – ident: 10.1016/j.cpccr.2025.100396_bib0009 – volume: 16 year: 2025 ident: 10.1016/j.cpccr.2025.100396_bib0016 article-title: Immunomodulatory effects of radiotherapy in the tumor microenvironment: current evidence and clinical applications publication-title: Front. Immunol. – volume: 14 start-page: 4575 year: 2022 ident: 10.1016/j.cpccr.2025.100396_bib0003 article-title: Evaluating the combined anticancer response of checkpoint inhibitor immunotherapy and FAP-targeted molecular radiotherapy in murine models of melanoma and lung cancer publication-title: Cancers (Basel) doi: 10.3390/cancers14194575 – volume: 81 start-page: 185 year: 2012 ident: 10.1016/j.cpccr.2025.100396_bib0006 article-title: A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer publication-title: Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.2011.03.008 – volume: 9 start-page: 835 year: 2019 ident: 10.1016/j.cpccr.2025.100396_bib0014 article-title: Effect of radiotherapy combined with pembrolizumab on local tumor control in mucosal melanoma patients publication-title: Front. Oncol. doi: 10.3389/fonc.2019.00835 – volume: 2011 year: 2011 ident: 10.1016/j.cpccr.2025.100396_bib0001 article-title: Primary malignant melanoma of the uterine cervix treated with ultraradical surgery: a case report publication-title: ISRN Obstet. Gynecol. doi: 10.5402/2011/683020 – volume: 12 year: 2022 ident: 10.1016/j.cpccr.2025.100396_bib0004 article-title: Effective combinations of immunotherapy and radiotherapy for cancer treatment publication-title: Front. Oncol. – volume: 366 start-page: 2443 year: 2012 ident: 10.1016/j.cpccr.2025.100396_bib0010 article-title: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1200690 – volume: 13 year: 2023 ident: 10.1016/j.cpccr.2025.100396_bib0020 article-title: Immunotherapy for mucosal melanoma: a literature review publication-title: Front. Oncol. – volume: 57 start-page: 83 year: 2024 ident: 10.1016/j.cpccr.2025.100396_bib0012 article-title: Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series publication-title: Med. Mol. Morphol. doi: 10.1007/s00795-023-00377-6 |
| SSID | ssj0002511974 |
| Score | 2.310961 |
| Snippet | •Cervical malignant melanoma is very rare and has no standard treatment.•Nivolumab plus radiotherapy was used as the initial treatment in this case.•Tumor... Highlights•Cervical malignant melanoma is very rare and has no standard treatment •Nivolumab plus radiotherapy was used as the initial treatment in this case... •Cervical malignant melanoma is very rare and has no standard treatment•Nivolumab plus radiotherapy was used as the initial treatment in this case•Tumor... |
| SourceID | crossref elsevier |
| SourceType | Index Database Publisher |
| StartPage | 100396 |
| SubjectTerms | Cervix Hematology, Oncology, and Palliative Medicine Immune checkpoint inhibitor Nivolumab Primary malignant melanoma Radiotherapy |
| Title | Primary advanced malignant melanoma of the uterine cervix treated with a combination of nivolumab and concurrent radiotherapy: A case report |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666621925000481 https://www.clinicalkey.es/playcontent/1-s2.0-S2666621925000481 https://dx.doi.org/10.1016/j.cpccr.2025.100396 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2666-6219 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511974 issn: 2666-6219 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2666-6219 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511974 issn: 2666-6219 databaseCode: M~E dateStart: 20200101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELbKghAXxFNbHisfuC2p0jRxYm5VtQgJtazYrthb5Lg2zXabVE27lAu_gH_Kn2D8SoNanhKXqLUydeL5OvPZnhkj9KKXRT3eZdKjhMdeSCLpJbzLvQi-MukTKmWoD5uIR6Pk4oKetlrfXC7M9VVcFMlmQxf_VdXQBspWqbN_oe76R6EBPoPS4Qpqh-sfKf7U1o_ou939IVDtjyre5XgorlhRzpkLDDhf6eS_44EyGJvjsSKQIPBB57spUwHT5ppSjnJtyVim9xsGZcFtaaf3bJLbPK7PNtEdXKOl9k3y62pB2UNsdCQuV8-47BgRu4FROwE2L-3eUj4Fy1Njbb1cz9gnTXvPprrM7DLfCq1M5k7F5nXjuxnLTMjjNJ-xWdlc6wiiRtyINonAJohHnJEVe9qMGe6qlGPScOrbhh2XYVYvLjt8wbkqEBtEnaZ4s0D3yeBt16uCju-dqV5Vp0FkSu78eLOZXqVVkPrpzq030M0gjqgywcMv2wXBQO_oqiiI-o1clSwdj7jzfPuZVIMdje-hu3Zag_sGjvdRSxQP0O2hDdx4iL5aVGKHSlyjEjtU4lJigBG2qMQGldiiEitUYoYbqFQCNSoxoBJvUYmbqHyF-1gBDBtMPkLnr0_GgzeePQjE4zBoxBNdBtMYX8SEToDfZnEwIVkiYOoeU-lHWShkj4YSXJFqzGhMI5oFZJKQhPfUwViP0UFRFuIQYUmDOJA-97tZLwT2zkTGApqQTMYw6r5oo5duUNOFGZnUBUJeploHqdJBanTQRqEb-NSlMoPzTQFcvxaL94mJytqRKv0ZeNqI1JKWIxvu-7sun_xzl0_Rne1_8Rk6WC3X4jm6xa9XebU80otYRxrK3wEVid-1 |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Primary+Advanced+Malignant+Melanoma+of+the+Uterine+Cervix+Treated+With+a+Combination+of+Nivolumab+and+Concurrent+Radiotherapy%3A+A+Case+Report&rft.jtitle=Current+problems+in+cancer.+Case+reports&rft.au=Kamo%2C+Norihito&rft.au=Furukawa%2C+Shigenori&rft.au=Kato%2C+Asami&rft.au=Okabe%2C+Chikako&rft.date=2025-12-01&rft.issn=2666-6219&rft.eissn=2666-6219&rft.spage=100396&rft.epage=100396&rft_id=info:doi/10.1016%2Fj.cpccr.2025.100396&rft.externalDBID=ECK1-s2.0-S2666621925000481&rft.externalDocID=1_s2_0_S2666621925000481 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2666-6219&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2666-6219&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2666-6219&client=summon |